Strontium ranelate for preventing and treating postmenopausal osteoporosis

Area of Science:

• Osteoporosis Research
• Pharmacological Interventions
• Bone Health

Background:

• Osteoporosis poses a significant health challenge for postmenopausal women.
• Strontium ranelate is a novel therapeutic agent for osteoporosis requiring efficacy and safety evaluation.

Purpose of the Study:

• To assess the effectiveness and safety of strontium ranelate in treating and preventing postmenopausal osteoporosis.
• To analyze its impact on fracture incidence, bone mineral density (BMD), and quality of life.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) published between 1996 and 2005.
• Inclusion criteria focused on RCTs of at least one-year duration comparing strontium ranelate with placebo in postmenopausal women.

Main Results:

• Strontium ranelate (2 g daily) significantly reduced vertebral fractures by 37% and non-vertebral fractures by 14% over three years.
• Significant increases in BMD at the lumbar spine, femoral neck, and total hip were observed in both treatment and prevention populations.
• Diarrhea was a noted side effect, but serious adverse events, study withdrawals, and mortality were not increased.

Conclusions:

• Strontium ranelate demonstrates efficacy in reducing fractures and increasing BMD in postmenopausal women with and without osteoporosis.
• While generally well-tolerated, potential risks to the vascular and neurological systems warrant further investigation.
• The evidence supports strontium ranelate as a valuable option for osteoporosis management.